Table 2 Affinity of nivolumab, pembrolizumab and prolgolimab to FcγRs and FcRn. The binding kinetics of anti-PD-1 antibodies to FcγRs and FcRn were determined by biolayer interferometry. Biotinylated receptors were immobilized on Streptavidin (SA) sensor, anti-PD-1 antibodies were in solution.
From: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Receptor | KD, M | |||||
|---|---|---|---|---|---|---|
Nivolumab | Pembrolizumab | Prolgolimab | ||||
Mean | SD | Mean | SD | Mean | SD | |
FcγRIa | 7.4 × 10–8 | 1.91 × 10–08 | 8.50 × 10–8 | 2.43 × 10–08 | 9.00 × 10–7 | 2.12 × 10–07 |
FcγRIIa (131R) | 2.00 × 10–6 | 1.53 × 10–08 | 5.17 × 10–6 | 7.83 × 10–07 | 9.66 × 10–6 | 4.09 × 10–07 |
FcγRIIa (131H) | 1.31 × 10–5 | 4.31 × 10–07 | 1.11 × 10–5 | 8.73 × 10–07 | 1.46 × 10–5 | 1.66 × 10–07 |
FcγRIIb | 9.30 × 10–7 | 7.23 × 10–09 | 8.64 × 10–6 | 4.75 × 10–07 | 2.10 × 10–5 | 1.81 × 10–06 |
FcγRIIIa (158V) | 8.97 × 10–6 | 4.73 × 10–07 | 5.24 × 10–6 | 1.31 × 10–07 | 1.33 × 10–6 | 5.77 × 10–08 |
FcγRIIIa (158F) | 1.66 × 10–5 | 6.18 × 10–07 | 1.99 × 10–5 | 4.81 × 10–07 | 1.27 × 10–5 | 5.77 × 10–07 |
FcRn | 2.48 × 10–8 | 1.40 × 10–10 | 2.5 × 10–8 | 1.01 × 10–10 | 1.53 × 10–8 | 6.47 × 10–10 |
